Vortrag
Dupilumab improves histologic and endoscopic aspects of eosinophilic esophagitis (EoE), as well as rate of weight gain, in children aged 1 to < 12 years: 52-week results from the Phase 3 EoE KIDS trial
Speaker
Vortrag
Dupilumab treatment reduces the frequency of dysphagia days and actions to relieve dysphagia in patients with eosinophilic esophagitis: Results from the phase 3 LIBERTY-EoE-TREET study
Speaker